Cargando…
Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
OBJECTIVES: We aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-line treatment in KRAS wild-type (WT), pan-RAS WT a...
Autores principales: | Lee, Shing Fung, Choi, Horace C. W., Chan, Sik Kwan, Lam, Ka On, Lee, Victor H. F., Wong, Irene O. L., Chiang, Chi Leung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127841/ https://www.ncbi.nlm.nih.gov/pubmed/34012917 http://dx.doi.org/10.3389/fonc.2021.651299 |
Ejemplares similares
-
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
por: Nannini, Margherita, et al.
Publicado: (2014) -
Quadruple wild-type (WT) GIST: defining the subset of GIST that
lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways
por: Pantaleo, Maria A, et al.
Publicado: (2015) -
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST
por: Urbini, Milena, et al.
Publicado: (2019) -
WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014) -
The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells
por: Leibovich-Rivkin, Tal, et al.
Publicado: (2014)